Anticoagulant profile of subcutaneous enoxaparin in healthy dogs.
factor Xa
heparin
hypercoagulability
pharmacodynamic
pharmacokinetic
thromboembolism
Journal
Journal of veterinary pharmacology and therapeutics
ISSN: 1365-2885
Titre abrégé: J Vet Pharmacol Ther
Pays: England
ID NLM: 7910920
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
revised:
16
08
2021
received:
08
05
2021
accepted:
12
09
2021
pubmed:
9
10
2021
medline:
12
1
2022
entrez:
8
10
2021
Statut:
ppublish
Résumé
Our study objective was to identify a subcutaneous enoxaparin dosage that provided a consistent anticoagulant intensity in dogs. Our hypotheses were that a dose of 0.8 mg/kg would provide inconsistent anticoagulation, a higher dose would provide consistent anticoagulation over a greater duration of time, and viscoelastometry would effectively monitor the anticoagulant status. Six healthy dogs received two subcutaneous enoxaparin doses (0.8 and 2 mg/kg) for anti-Xa activity determinations and pharmacokinetic modeling. Based on calculations derived from these results, 1.3 mg/kg, SC, q8 h was administered for seven doses. Target ranges for anticoagulant intensity were defined as anti-Xa activity of 0.5-1 U/ml, and change from baseline of two viscoelastometric parameters: activated clotting time (ΔACT; ≥40 s), and clot rate (CRpost; ≤20 U/min). Following an initial injection at 1.3 mg/kg, anti-Xa activity of 5/6 dogs reached or exceeded the target range. Following the final dose, anti-Xa activity reached or exceeded the target range in all dogs, and ΔACT and CRpost values exceeded target for 2-6 and 4-12 h, respectively. At an enoxaparin dosage of 1.3 mg/kg, SC, q8 h, anti-Xa activity was consistently above the minimum threshold of the target range; however, the safety of this dosage remains to be determined.
Substances chimiques
Anticoagulants
0
Enoxaparin
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
34-45Subventions
Organisme : College of Veterinary Medicine, Mississippi State University
Informations de copyright
© 2021 John Wiley & Sons Ltd.
Références
Babski, D. M., Brainard, B. M., Krimer, P. M., Ralph, A. G., Pittman, J. R., & Koenig, A. (2012). Sonoclot evaluation of whole blood coagulation in healthy adult dogs. Journal of Veterinary Emergency and Critical Care, 22(6), 646-652. https://doi.org/10.1111/j.1476-4431.2012.00820.x
Blais, M. C., Bianco, D., Goggs, R., Lynch, A. M., Palmer, L., Ralph, A., & Sharp, C. R. (2019). Consensus on the rational use of antithrombotics in veterinary critical care (CURATIVE): Domain 3-Defining antithrombotic protocols. Journal of Veterinary Emergency and Critical Care (San Antonio), 29(1), 60-74. https://doi.org/10.1111/vec.12795
Blois, S. L., Lang, S. T., Wood, R. D., & Monteith, G. (2015). Biologic variability and correlation of platelet function testing in healthy dogs. Veterinary Clinical Pathology, 44, 503-510. https://doi.org/10.1111/vcp.12290
Boneu, B., & De Moerloose, P. (2001). How and when to monitor a patient treated with low molecular weight heparin. Seminars in Thrombosis and Hemostasis, 27, 519-522. https://doi.org/10.1055/s-2001-17961
Brainard, B. M., Koenig, A., Babski, D. M., Blong, A. E., & Scherk, J. R. (2012). Viscoelastic pharmacodynamics after dalteparin administration to healthy dogs. American Journal of Veterinary Research, 73, 1577-1582. https://doi.org/10.2460/ajvr.73.10.1577
Brooks, M. B. (2004). Evaluation of a chromogenic assay to measure the factor Xa inhibitory activity of unfractionated heparin in canine plasma. Veterinary Clinical Pathology, 33, 208-214. https://doi.org/10.1111/j.1939-165X.2004.tb00375.x
Clauss, A. (1957). Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematologica, 17(4), 237-246. https://doi.org/10.1159/000205234
Furuhashi, M., Ura, N., Hasegawa, K., Yoshida, H., Tsuchihashi, K., Miura, T., & Shimamoto, K. (2002). Sonoclot coagulation analysis: New bedside monitoring for determination of the appropriate heparin dose during haemodialysis. Nephrology Dialysis Transplantation, 17, 1457-1462. https://doi.org/10.1093/ndt/17.8.1457
Goggs, R., Blais, M. C., Brainard, B. M., Chan, D. L., deLaforcade, A. M., Rozanski, E., & Sharp, C. R. (2019). American College of Veterinary Emergency and Critical Care (ACVECC) consensus on the rational use of antithrombotics in veterinary critical care (Curative) guidelines: Small animal. Journal of Veterinary Emergency and Critical Care, 29, 12-36. https://doi.org/10.1111/vec.12801
Helmond, S. E., Polzin, D. J., Armstrong, P. J., Finke, M., & Smith, S. A. (2010). Treatment of immune-mediated hemolytic anemia with individually adjusted heparin dosing in dogs. Journal of Veterinary Internal Medicine, 24, 597-605. https://doi.org/10.1111/j.1939-1676.2010.0505.x
Hirsch, J., & Raschke, R. (2004). Heparin and low molecular weight heparians: The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest, 126, 188S-203S. https://doi.org/10.1378/chest.126.3_suppl.188S
Ignasiak, D. P., McClanahan, T. B., Bousley, R. E., Juneau, P. L., & Gallagher, K. P. (1998). Effects of intravenous enoxaparin and intravenous inogatran in an electrolytic injury model of venous thrombosis in the dog. Journal of Thrombosis and Thrombolysis, 6, 199-206. https://doi.org/10.1023/A:1008806312396
Johnson, L. R., Lappin, M. R., & Baker, D. C. (1999). Pulmonary thromboembolism in 29 dogs: 1985-1995. Journal of Veterinary Internal Medicine, 13, 338-345. https://doi.org/10.1892/0891-6640(1999)013<0338:ptid>2.3.co;2
Kuzi, S., Segev, G., Haruvi, E., & Aroch, I. (2010). Plasma antithrombin activity as a diagnostic and prognostic indicator in dogs: A retrospective study of 149 dogs. Journal of Veterinary Internal Medicine, 24, 587-596. https://doi.org/10.1111/j.1939-1676.2010.0497.x
Leadley, R. J., Kasiewski, C. J., Bostwick, J. S., Bentley, R., McVey, M. J., White, F. J., Perrone, M. H., & Dunwiddie, C. T. (1997). Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery. Thrombosis and Haemostasis, 78, 1278-1285. https://doi.org/10.1055/s-0038-1657728
Lee, B., Al-Waili, N., Butler, G., & Salom, K. (2011). Assessment of heparin anticoagulation by Sonoclot analyzer in arterial reconstruction surgery. Technology and Health Care, 19, 109-114. https://doi.org/10.3233/THC-2011-0612
Libersan, D., Khalil, A., Dagenais, P., Quan, E., Delorme, F., Uzan, A., & Latour, J. G. (1998). The low molecular weight heparin, enoxaparin, limits infarct size at reperfusion in the dog. Cardiovascular Research, 37, 656-666. https://doi.org/10.1016/S0008-6363(97)00292-7
Lunsford, K. V., Mackin, A. J., Langston, V. C., & Brooks, M. (2014). Pharmacokinetics of subcutaneous low molecular weight heparin (Enoxaparin) in dogs. Journal of the American Animal Hospital Association, 45, 261-267. https://doi.org/10.5326/0450261
Maeckelbergh, V. A., & Acierno, M. J. (2008). Comparison of prothrombin time, activated partial thromboplastin time, and fibrinogen concentration in blood samples collected via an intravenous catheter versus direct venipuncture in dogs. American Journal of Veterinary Research, 69, 868-873. https://doi.org/10.2460/ajvr.69.7.868
Mestre, M., Uzan, A., Sedivy, P., & Cavero, I. (1992). Enoxaparin (Clexane®, Lovenox®), a low molecular weight heparin, enhances t-PA-induced coronary thrombus lysis in anesthetized dogs without inducing hypocoagulability. Thrombosis Research, 66, 191-206. https://doi.org/10.1016/0049-3848(92)90189-H
Panek, C. M., Nakamura, R. K., & Bianco, D. (2015). Use of enoxaparin in dogs with primary immune-mediated hemolytic anemia: 21 cases. Journal of Veterinary Emergency and Critical Care, 25, 273-277. https://doi.org/10.1111/vec.12286
Pouzot-Nevoret, C., Barthelemy, A., Cluzel, M., Verwaerde, P., Bonnet-Garin, J. M., & Goy-Thollot, I. (2016). Enoxaparin has no significant anticoagulation activity in healthy Beagles at a dose of 0.8 mg/kg four times daily. The Veterinary Journal, 210, 98-100. https://doi.org/10.1016/j.tvjl.2016.01.018
Rebello, S. S., Kasiewski, C. J., Bentley, R. G., Morgan, S. R., Chu, V., Bostwick, J. S., Klein, S. I., Perrone, M. H., & Leadley, R. J. (2001). Superiority of enoxaparin over heparin in combination with a GPIIb/IIIa receptor antagonist during coronary thrombolysis in dogs. Thrombosis Research, 102, 261-271. https://doi.org/10.1016/S0049-3848(01)00242-0
Riviere, J. E. (1999). Comparative pharmacokinetics: Principles, techniques, and applications. Iowa State University Press.
Saati, S., Abrams-Ogg, A. C. G., Blois, S. L., & Wood, R. D. (2018). Comparison of multiplate, Platelet Function Analyzer-200, and plateletworks in healthy dogs treated with aspirin and clopidogrel. Journal of Veterinary Internal Medicine, 32, 111-118. https://doi.org/10.1111/jvim.14886
Schött, U., Nilsson, L. G., Broman, M., & Engström, M. (2010). Monitoring of low molecular weight heparin anticoagulation during haemodialysis with a Sonoclot Analyzer. Perfusion, 25, 191-196. https://doi.org/10.1177/0267659110374675
Shinoda, T., Arakura, H., Katakura, M., Shirota, T., & Nakagawa, S. (1990). Usefulness of thrombelastography for dosage monitoring of low molecular weight heparin and unfractionated heparin during hemodialysis. Artificial Organs, 14, 413-415. https://doi.org/10.1111/j.1525-1594.1990.tb02996.x
Swann, J. W., Garden, O. A., Fellman, C. L., Glanemann, B., Goggs, R., LeVine, D. N., Mackin, A. J., & Whitley, N. T. (2019). ACVIM consensus statement on the treatment of immune-mediated hemolytic anemia in dogs. Journal of Veterinary Internal Medicine, 33, 1141-1172. https://doi.org/10.1111/jvim.15463
Van De Wiele, C. M., Hogan, D. F., Green 3rd, H. W., & Sederquist, K. D. (2010). Antithrombotic effect of enoxaparin in clinically healthy cats: A venous stasis model. Journal of Veterinary Internal Medicine, 24, 185-191. https://doi.org/10.1111/j.1939-1676.2009.0412.x
Van, P. Y., Cho, S. D., Underwood, S. J., Morris, M. S., Waters, J. M., & Schreiber, M. A. (2009). Thrombelastography versus antifactor Xa levels in the assessment of prophylactic-dose enoxaparin in critically ill patients. Journal of Trauma: Injury, Infection & Critical Care, 66, 1509-1515. https://doi.org/10.1097/TA.0b013e3181a51e33
Weinkle, T. K., Center, S. A., Randolph, J. F., Warner, K. L., Barr, S. C., & Erb, H. N. (2005). Evaluation of prognostic factors, survival rates, and treatment protocols for immune-mediated hemolytic anemia in dogs: 151 cases (1993-2002). Journal of the American Veterinary Medical Association, 226, 1869-1880. https://doi.org/10.2460/javma.2005.226.1869